Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Transl Res. 2020 Mar 16;220:138–152. doi: 10.1016/j.trsl.2020.03.004

Figure 3. Trivalent nucleoside-modified mRNA-LNP vaccine.

Figure 3.

The trivalent gC2, gD2, gE2 nucleoside-modified mRNA-LNP vaccine combines the concept of blocking immune evasion with the use of nucleoside-modified mRNA for vaccine delivery. Modifications in mRNA include substitution of uridine residues with 1-methyl-pseudouridine to reduce triggering innate immune sensors that degrade mRNA, and altering the 5’ cap, 5’ and 3’ UTRs and poly(A) tail to improve mRNA stability. Modified mRNA is purified to remove double stranded RNA using HPLC followed by encapsulation in LNPs.